Research progress of clinicopathology, diagnosis and treatment of invasive micropapillary carcinoma of the breast_CHINESE JOURNAL OF BASES AND CLINICS IN GENERAL SURGERY

Authors：

WANG Yuechen , TANG Lu ,  XING Hua ,  ZHENG Zelin

Department of Breast Surgery, China-Japan Union Hospital of Jilin University, Changchun 130033, P. R. China;

Corresponding author：

XING Hua, Email: xinghua1967@163.com; ZHENG Zelin, Email: zelinzheng@126.com

Keywords：

breast carcinoma; invasive micropapillary carcinoma; invasive ductal carcinoma; pathology

DOI：

10.7507/1007-9424.201812006

Video：

Export PDF Favorites Scan Get Citation

Abstract Full text Figures/Tables Video References Cited by

Objective To investigate the clinicopathological features, diagnosis and treatment of invasive micropapillary carcinoma (IMPC) of the breast.Method The relevant literatures at home and abroad in recent years about the clinical features, pathological features and diagnosis and treatment of IMPC were reviewed.Results IMPC is in low incidence and mostly in mixture. Because the clinical manifestations of IMPC and invasive ductal carcinoma of breast are basically similar, only the typical pathological features in pathological examination can confirm the diagnosis as " inside-out growth pattern” and " morula-like clusters of cancer cells surrounded by clear stromal spaces”.Conclusions IMPC is a special subtype of breast invasive carcinoma, which should be pay enough attention to it in clinic due to its unique microscopic morphology, high vessel invasiveness and high lymph node metastasis rate, high malignancy, poor prognosis and so on.

Citation： WANG Yuechen, TANG Lu, XING Hua, ZHENG Zelin. Research progress of clinicopathology, diagnosis and treatment of invasive micropapillary carcinoma of the breast. CHINESE JOURNAL OF BASES AND CLINICS IN GENERAL SURGERY, 2019, 26(5): 636-640. doi: 10.7507/1007-9424.201812006 Copy

1.	Fisher ER, Palekar AS, Redmond C, et al. Pathologic findings from the National Surgical Adjuvant Breast Project (protocol no.4). Ⅵ. Invasive papillary cancer. Am J Clin Pathol, 1980, 73(3): 313-322.
2.	Siriaunkgul S, Tavassoli FA. Invasive micropapillary carcinoma of the breast. Mod Pathol, 1993, 6(6): 660-662.
3.	皋岚湘, 丁华野. WHO 乳腺肿瘤组织学分类 (2003). 临床与实验病理学杂志, 2004, 20(1): 3-4.
4.	张祥盛. WHO (2012) 乳腺肿瘤组织学分类. 诊断病理学杂志, 2012, 19(6): 477-478.
5.	Yang YL, Liu BB, Zhang X, et al. Invasive micropapillary carcinoma of the breast: An update. Arch Pathol Lab Med, 2016, 140(8): 799-805.
6.	姚建国, 刘颖. 浸润性微乳头状癌的临床病理研究现状. 临床与实验病理学杂志, 2016, 32(12): 1379-1382.
7.	Ye FG, Xia C, Ma D, et al. Nomogram for predicting preoperative lymph node involvement in patients with invasive micropapillary carcinoma of breast: a SEER population-based study. BMC Cancer, 2018, 18(1): 1-9.
8.	Chen AC, Paulino AC, Schwartz MR, et al. Population-based comparison of prognostic factors in invasive micropapillary and invasive ductal carcinoma of the breast. Br J Cancer, 2014, 111(3): 619-622.
9.	Alsharif S, Daghistani R, Kamberoğlu EA, et al. Mammographic, sonographic and MR imaging features of invasive micropapillary breast cancer. Eur J Radiol, 2014, 83(8): 1375-1380.
10.	苏晓慧, 林青, 崔春晓, 等. 乳腺浸润性微乳头状癌的影像学表现与免疫组化的相关性研究. 医学影像学杂志, 2016, 26(2): 258-262.
11.	陈园园, 张嫣, 王霞, 等. 乳腺浸润性微乳头状癌的 MRI 表现及临床病理特点. 中国 CT 和 MRI 杂志, 2018, 16(4): 80-82.
12.	Lim HS, Kuzmiak CM, Jeong SI, et al. Invasive micropapillary carcinoma of the breast: MR imaging findings. Korean J Radiol, 2013, 14(4): 551-558.
13.	Baba S, Isoda T, Maruoka Y, et al. Diagnostic and prognostic value of pretreatment SUV in 18F-FDG/PET in breast cancer: comparison with apparent diffusion coefficient from diffusion-weighted MR imaging. J Nucl Med, 2014, 55(5): 736-742.
14.	Yun SU, Choi BB, Shu KS, et al. Imaging findings of invasive micropapillary carcinoma of the breast. J Breast Cancer, 2012, 15(1): 57-64.
15.	内山瞳, 松井成明, 森下明博, 等. 乳腺原発 invasive micropapillary carcinoma の細胞学的検討. 日本臨床細胞学会雑誌, 2016, 55(3): 148-153.
16.	郭晓静, 陈凌, 郎荣刚, 等. 乳腺浸润性微乳头状癌的病理学特征与淋巴结转移的关系. 中华病理学杂志, 2006, 35(1): 8-12.
17.	Kaya C, Uçak R, Bozkurt E, et al. The impact of micropapillary component ratio on the prognosis of patients with invasive micropapillary breast carcinoma. J Invest Surg, 2018, 29: 1-9.
18.	Collins K, Ricci A Jr. Micropapillary variant of mucinous breast carcinoma: A distinct subtype. Breast J, 2018, 24(3): 339-342.
19.	李晓艳, 刘芳芳, 李振华, 等. 乳腺具有微乳头状结构黏液癌的免疫表型及预后研究. 中国肿瘤临床, 2015, 42(8): 411-415.
20.	付丽, 付笑影, 刘彤华. 乳腺浸润性微乳头状癌的形态改变与生物学行为的关系. 中华病理学杂志, 2004, 33(1): 21-25.
21.	吴楠, 李莹, 吴梓政, 等. 195 例乳腺浸润性微乳头状癌临床病理及预后分析. 中华普通外科杂志, 2017, 32(5): 397-401.
22.	Tang SL, Yang JQ, Du ZG, et al. Clinicopathologic study of invasive micropapillary carcinoma of the breast. Oncotarget, 2017, 8(26): 42455-42465.
23.	倪小健, 匡夏颖, 周平, 等. 基于多中心的中国乳腺浸润性微乳头状癌的临床特征分析. 中国临床医学, 2018, 25(4): 578-580.
24.	陈洁, 吕青, 王竹. 常用乳腺癌诊治指南中对单纯乳腺原位癌诊治推荐的比较. 中国普外基础与临床杂志, 2017, 24(11): 1400-1407.
25.	Stewart RL, Caron JE, Gulbahce EH, et al. HER2 immunohistochemical and fluorescence in situ hybridization discordances in invasive breast carcinoma with micropapillary features. Mod Pathol, 2017, 30(11): 1561-1566.
26.	Wolff AC, Hammond MEH, Allison KH, et al. Human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology/College of American Pathologists clinical practice guideline focused update. Arch Pathol Lab Med, 2018, 142(11): 1364-1382.
27.	Badyal RK, Bal A, Das A, et al. Invasive micropapillary carcinoma of the breast: immunophenotypic analysis and role of cell adhesion molecules (CD44 and E-cadherin) in nodal metastasis. Appl Immunohistochem Mol Morphol, 2016, 24(3): 151-158.
28.	Umeda T, Ishida M, Murata S, et al. Immunohistochemical analyses of CD44 variant isoforms in invasive micropapillary carcinoma of the breast: comparison with a concurrent conventional invasive carcinoma of no special type component. Breast Cancer, 2016, 23(6): 869-875.
29.	Mercogliano MF, Inurrigarro G, De Martino M, et al. Invasive micropapillary carcinoma of the breast overexpresses MUC4 and is associated with poor outcome to adjuvant trastuzumab in HER2-positive breast cancer. BMC Cancer, 2017, 17(1): 895.
30.	Mercogliano MF, De Martino M, Venturutti L, et al. TNFα-induced mucin 4 expression elicits trastuzumab resistance in HER2-positive breast cancer. Clin Cancer Res, 2017, 23(3): 636-648.
31.	Meng F, Liu B, Xie G, et al. Amplification and overexpression of PSCA at 8q24 in invasive micropapillary carcinoma of breast. Breast Cancer Res Treat, 2017, 166(2): 383-392.
32.	姜军. 特殊类型乳腺癌分类及诊治原则. 中国实用外科杂志, 2013, 33(3): 174-175.
33.	Doublier S, Belisario DC, Polimeni M, et al. HIF-1 activation induces doxorubicin resistance in MCF7 3-D spheroids via P-glycoprotein expression: a potential model of the chemo-resistance of invasive micropapillary carcinoma of the breast. BMC Cancer, 2012, 12: 4.
34.	Wu SG, Zhang WW, Sun JY, et al. Postoperative radiotherapy for invasive micropapillary carcinoma of the breast: an analysis of surveillance, epidemiology, and end results database. Cancer Manag Res, 2017, (9): 453-459.
35.	Yu JI, Choi DH, Huh SJ, et al. Differences in prognostic factors and failure patterns between invasive micropapillary carcinoma and carcinoma with micropapillary component versus invasive ductal carcinoma of the breast: retrospective multicenter case–control study (KROG 13-06). Clin Breast Cancer, 2015, 15(5): 353-361.
36.	罗蒙, 许春景, 孙雨婷, 等. HER2 阳性乳腺癌的靶向治疗及其耐药机制. 实用肿瘤杂志, 2018, 33(3): 283-288.
37.	Lei S, Zhanhong C, Xiaojia W. ASCO 2018: recent advances in endocrine therapy for advanced breast cancer. Chin J Clin Oncol, 2018, 45(18): 919-921.
38.	华彬, 陆旭, 肖文政, 等. 乳腺浸润性微乳头状癌与浸润性导管癌预后比较的单中心回顾性病例配对研究. 中华外科杂志, 2018, 56(1): 56-60.
39.	Wu Y, Zhang N, Yang Q. The prognosis of invasive micropapillary carcinoma compared with invasive ductal carcinoma in the breast: a meta-analysis. BMC Cancer, 2017, 17(1): 839.

1. Fisher ER, Palekar AS, Redmond C, et al. Pathologic findings from the National Surgical Adjuvant Breast Project (protocol no.4). Ⅵ. Invasive papillary cancer. Am J Clin Pathol, 1980, 73(3): 313-322.
2. Siriaunkgul S, Tavassoli FA. Invasive micropapillary carcinoma of the breast. Mod Pathol, 1993, 6(6): 660-662.
3. 皋岚湘, 丁华野. WHO 乳腺肿瘤组织学分类 (2003). 临床与实验病理学杂志, 2004, 20(1): 3-4.
4. 张祥盛. WHO (2012) 乳腺肿瘤组织学分类. 诊断病理学杂志, 2012, 19(6): 477-478.
5. Yang YL, Liu BB, Zhang X, et al. Invasive micropapillary carcinoma of the breast: An update. Arch Pathol Lab Med, 2016, 140(8): 799-805.
6. 姚建国, 刘颖. 浸润性微乳头状癌的临床病理研究现状. 临床与实验病理学杂志, 2016, 32(12): 1379-1382.
7. Ye FG, Xia C, Ma D, et al. Nomogram for predicting preoperative lymph node involvement in patients with invasive micropapillary carcinoma of breast: a SEER population-based study. BMC Cancer, 2018, 18(1): 1-9.
8. Chen AC, Paulino AC, Schwartz MR, et al. Population-based comparison of prognostic factors in invasive micropapillary and invasive ductal carcinoma of the breast. Br J Cancer, 2014, 111(3): 619-622.
9. Alsharif S, Daghistani R, Kamberoğlu EA, et al. Mammographic, sonographic and MR imaging features of invasive micropapillary breast cancer. Eur J Radiol, 2014, 83(8): 1375-1380.
10. 苏晓慧, 林青, 崔春晓, 等. 乳腺浸润性微乳头状癌的影像学表现与免疫组化的相关性研究. 医学影像学杂志, 2016, 26(2): 258-262.
11. 陈园园, 张嫣, 王霞, 等. 乳腺浸润性微乳头状癌的 MRI 表现及临床病理特点. 中国 CT 和 MRI 杂志, 2018, 16(4): 80-82.
12. Lim HS, Kuzmiak CM, Jeong SI, et al. Invasive micropapillary carcinoma of the breast: MR imaging findings. Korean J Radiol, 2013, 14(4): 551-558.
13. Baba S, Isoda T, Maruoka Y, et al. Diagnostic and prognostic value of pretreatment SUV in 18F-FDG/PET in breast cancer: comparison with apparent diffusion coefficient from diffusion-weighted MR imaging. J Nucl Med, 2014, 55(5): 736-742.
14. Yun SU, Choi BB, Shu KS, et al. Imaging findings of invasive micropapillary carcinoma of the breast. J Breast Cancer, 2012, 15(1): 57-64.
15. 内山瞳, 松井成明, 森下明博, 等. 乳腺原発 invasive micropapillary carcinoma の細胞学的検討. 日本臨床細胞学会雑誌, 2016, 55(3): 148-153.
16. 郭晓静, 陈凌, 郎荣刚, 等. 乳腺浸润性微乳头状癌的病理学特征与淋巴结转移的关系. 中华病理学杂志, 2006, 35(1): 8-12.
17. Kaya C, Uçak R, Bozkurt E, et al. The impact of micropapillary component ratio on the prognosis of patients with invasive micropapillary breast carcinoma. J Invest Surg, 2018, 29: 1-9.
18. Collins K, Ricci A Jr. Micropapillary variant of mucinous breast carcinoma: A distinct subtype. Breast J, 2018, 24(3): 339-342.
19. 李晓艳, 刘芳芳, 李振华, 等. 乳腺具有微乳头状结构黏液癌的免疫表型及预后研究. 中国肿瘤临床, 2015, 42(8): 411-415.
20. 付丽, 付笑影, 刘彤华. 乳腺浸润性微乳头状癌的形态改变与生物学行为的关系. 中华病理学杂志, 2004, 33(1): 21-25.
21. 吴楠, 李莹, 吴梓政, 等. 195 例乳腺浸润性微乳头状癌临床病理及预后分析. 中华普通外科杂志, 2017, 32(5): 397-401.
22. Tang SL, Yang JQ, Du ZG, et al. Clinicopathologic study of invasive micropapillary carcinoma of the breast. Oncotarget, 2017, 8(26): 42455-42465.
23. 倪小健, 匡夏颖, 周平, 等. 基于多中心的中国乳腺浸润性微乳头状癌的临床特征分析. 中国临床医学, 2018, 25(4): 578-580.
24. 陈洁, 吕青, 王竹. 常用乳腺癌诊治指南中对单纯乳腺原位癌诊治推荐的比较. 中国普外基础与临床杂志, 2017, 24(11): 1400-1407.
25. Stewart RL, Caron JE, Gulbahce EH, et al. HER2 immunohistochemical and fluorescence in situ hybridization discordances in invasive breast carcinoma with micropapillary features. Mod Pathol, 2017, 30(11): 1561-1566.
26. Wolff AC, Hammond MEH, Allison KH, et al. Human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology/College of American Pathologists clinical practice guideline focused update. Arch Pathol Lab Med, 2018, 142(11): 1364-1382.
27. Badyal RK, Bal A, Das A, et al. Invasive micropapillary carcinoma of the breast: immunophenotypic analysis and role of cell adhesion molecules (CD44 and E-cadherin) in nodal metastasis. Appl Immunohistochem Mol Morphol, 2016, 24(3): 151-158.
28. Umeda T, Ishida M, Murata S, et al. Immunohistochemical analyses of CD44 variant isoforms in invasive micropapillary carcinoma of the breast: comparison with a concurrent conventional invasive carcinoma of no special type component. Breast Cancer, 2016, 23(6): 869-875.
29. Mercogliano MF, Inurrigarro G, De Martino M, et al. Invasive micropapillary carcinoma of the breast overexpresses MUC4 and is associated with poor outcome to adjuvant trastuzumab in HER2-positive breast cancer. BMC Cancer, 2017, 17(1): 895.
30. Mercogliano MF, De Martino M, Venturutti L, et al. TNFα-induced mucin 4 expression elicits trastuzumab resistance in HER2-positive breast cancer. Clin Cancer Res, 2017, 23(3): 636-648.
31. Meng F, Liu B, Xie G, et al. Amplification and overexpression of PSCA at 8q24 in invasive micropapillary carcinoma of breast. Breast Cancer Res Treat, 2017, 166(2): 383-392.
32. 姜军. 特殊类型乳腺癌分类及诊治原则. 中国实用外科杂志, 2013, 33(3): 174-175.
33. Doublier S, Belisario DC, Polimeni M, et al. HIF-1 activation induces doxorubicin resistance in MCF7 3-D spheroids via P-glycoprotein expression: a potential model of the chemo-resistance of invasive micropapillary carcinoma of the breast. BMC Cancer, 2012, 12: 4.
34. Wu SG, Zhang WW, Sun JY, et al. Postoperative radiotherapy for invasive micropapillary carcinoma of the breast: an analysis of surveillance, epidemiology, and end results database. Cancer Manag Res, 2017, (9): 453-459.
35. Yu JI, Choi DH, Huh SJ, et al. Differences in prognostic factors and failure patterns between invasive micropapillary carcinoma and carcinoma with micropapillary component versus invasive ductal carcinoma of the breast: retrospective multicenter case–control study (KROG 13-06). Clin Breast Cancer, 2015, 15(5): 353-361.
36. 罗蒙, 许春景, 孙雨婷, 等. HER2 阳性乳腺癌的靶向治疗及其耐药机制. 实用肿瘤杂志, 2018, 33(3): 283-288.
37. Lei S, Zhanhong C, Xiaojia W. ASCO 2018: recent advances in endocrine therapy for advanced breast cancer. Chin J Clin Oncol, 2018, 45(18): 919-921.
38. 华彬, 陆旭, 肖文政, 等. 乳腺浸润性微乳头状癌与浸润性导管癌预后比较的单中心回顾性病例配对研究. 中华外科杂志, 2018, 56(1): 56-60.
39. Wu Y, Zhang N, Yang Q. The prognosis of invasive micropapillary carcinoma compared with invasive ductal carcinoma in the breast: a meta-analysis. BMC Cancer, 2017, 17(1): 839.

Previous Article
Progress in the application of glutamine in nutritional support after hepatectomy

CHINESE JOURNAL OF BASES AND CLINICS IN GENERAL SURGERY

Research progress of clinicopathology, diagnosis and treatment of invasive micropapillary carcinoma of the breast

Abstract Full text Figures/Tables Video References Cited by

Previous Article

Format

Content